1. Home
  2. ASLE vs BWAY Comparison

ASLE vs BWAY Comparison

Compare ASLE & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerSale Corporation

ASLE

AerSale Corporation

HOLD

Current Price

$6.71

Market Cap

290.0M

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$17.85

Market Cap

337.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASLE
BWAY
Founded
2008
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Industrial Specialties
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
290.0M
337.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ASLE
BWAY
Price
$6.71
$17.85
Analyst Decision
Hold
Strong Buy
Analyst Count
2
2
Target Price
$7.00
$23.50
AVG Volume (30 Days)
496.2K
71.0K
Earning Date
11-06-2025
11-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
213.09
EPS
0.11
0.13
Revenue
$339,090,000.00
$49,094,000.00
Revenue This Year
$1.35
$330.76
Revenue Next Year
$19.09
$22.24
P/E Ratio
$59.26
$54.76
Revenue Growth
N/A
27.08
52 Week Low
$5.56
$7.84
52 Week High
$9.12
$18.05

Technical Indicators

Market Signals
Indicator
ASLE
BWAY
Relative Strength Index (RSI) 52.32 63.59
Support Level $6.33 $16.75
Resistance Level $6.75 $17.75
Average True Range (ATR) 0.22 0.82
MACD 0.11 0.23
Stochastic Oscillator 94.71 91.70

Price Performance

Historical Comparison
ASLE
BWAY

About ASLE AerSale Corporation

AerSale Corp is an integrated, diversified leader in aviation aftermarket products and services. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing a broad range of maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. The company operating segment includes Asset Management Solutions and TechOps. It generates maximum revenue from the Asset Management Solutions segment.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: